The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations
Open accessAbstract
Prostate cancer is a major public health problem in developed countries. The remarkable biological and clinical heterogeneity of prostate cancer provides unique opportunities as well as challenges for the diagnostic imaging evaluation of this prevalent disease. The disease is characterized by a natural history that ranges from localized slowly growing hormone-dependent tumor progressing to metastatic hormone-refractory disease. PET is an ideal imaging tool for noninvasive interrogation of the underlying tumor biology. 18F-FDG is the most common PET radiotracer used for oncological applications based upon elevated glucose metabolism in malignant tissue in comparison to normal tissue. FDG uptake in prostate cancer depends on tumor differentiation with low accumulation in well-differentiated tumors and high uptake in aggressive poorly differentiated tumors. Cumulative current evidence suggests that FDG PET may be useful in detection of disease in a small fraction of patients with biochemical recurrence, in the imaging evaluation of extent and treatment response in metastatic disease and in prediction of patient outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229
Moon, J.-S., Jin, W.-J., Kwak, J.-H., Kim, H.-J., Yun, M.-J., KIM, J.-W., Park, S. W., & Kim, K.-S. (2011) · Biochemical Journal · doi:10.1042/bj20101104 · Cited by 125
Cited by
Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., & Lawrentschuk, N. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.021 · Cited by 1,007
Afshar-Oromieh, A., Zechmann, C. M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Holland-Letz, T., Hadaschik, B. A., Giesel, F. L., Debus, J., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2525-5 · Cited by 921
Current use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 611
Functional expression of sodium-glucose transporters in cancer
Scafoglio, C., Hirayama, B. A., Kepe, V., Liu, J., Ghezzi, C., Satyamurthy, N., Moatamed, N. A., Huang, J., Koepsell, H., Barrio, J. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511698112 · Cited by 329
PET/MRI: Where might it replace PET/CT?
Ehman, E. C., Johnson, G. B., Villanueva‐Meyer, J. E., Cha, S., Leynes, A. P., Larson, P. E. Z., & Hope, T. A. (2017) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25711 · Cited by 271
Metadata
- Authors
- Jadvar, H.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2013-02-22
- Volume
- 40
- Issue
- S1
- Pages
- 5-10
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W1984585246
- Cited by
- 158
- References
- 2
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. https://app.cochat.ai/papers/10.1007/s00259-013-2361-7
- The paper
- Jadvar, H. (2013). Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-013-2361-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.